
The study aimed to estimate the cost-effectiveness of using SGLT2 inhibitors in the management of type 2 diabetes mellitus, taking into account their cardio- and reno-protective effects. The study found that introducing SGLT2 inhibitors was cost-effective for all subpopulations on treatment pathways reflecting the NG28-2022 guidelines, becoming cost-saving between 2 and 16 years post-initiation. Using SGLT2 inhibitors resulted in lower predicted lifetime costs than pathways reflecting the NG28-2015 guidelines and incremental gains in quality-adjusted life years, leading to dominance for the updated NG28-2022 guidance in all scenarios.
Like
Save
Share